Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
t-cell tags : Therapeutics save search
Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma
Published: 2024-04-15 (Crawled : 12:00) - globenewswire.com
VIRX | $0.8363 -1.36% -1.33% 55K
|
Manufacturing
|
| O: -12.71%
H: 0.97%
C: -24.27%
t-cell positive topline trial therapeutics results
Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting
Published: 2024-04-05 (Crawled : 21:00) - globenewswire.com
ELTX | $9.25 0.33% 0.32% 25K
|
| Email alert
Add to watchlist
plify-201 cell ongoing preclinical meeting eli-002 therapeutics response study
Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning
Published: 2024-04-04 (Crawled : 11:00) - biospace.com/
ACHL | $0.7838 0.35% -0.61% 120K
|
Manufacturing
|
| O: -16.22%
H: 0.99%
C: -7.89%
first melanoma update therapeutics advanced
CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
Published: 2024-04-03 (Crawled : 12:00) - globenewswire.com
CTMX | $1.63 -2.98% -2.75% 350K
|
Health Technology
|
| O: -0.47%
H: 2.35%
C: 0.94%
probody candidate t-cell collaboration therapeutics
CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas - March 18, 2024
Published: 2024-03-18 (Crawled : 16:00) - biospace.com/
CTMX | $1.63 -2.98% -2.75% 350K
|
Health Technology
|
| O: 0.97%
H: 0.48%
C: -3.35%
probody t-cell collaboration therapeutics milestone
CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
Published: 2024-03-18 (Crawled : 12:00) - globenewswire.com
CTMX | $1.63 -2.98% -2.75% 350K
|
Health Technology
|
| O: 0.97%
H: 0.48%
C: -3.35%
probody collaboration therapeutics milestone
Coya Therapeutics to Present Data on Immune System and Regulatory T Cell (Treg) Contributions in Frontotemporal Dementia (FTD) Patients at AD/PD 2024 Conference
Published: 2024-02-29 (Crawled : 15:00) - biospace.com/
COYA | News | $8.41 4.86% 3.14% 120K
|
|
| O: 0.0%
H: 1.1%
C: -5.86%
conference cell dementia system therapeutics
Viracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 Trial
Published: 2024-02-29 (Crawled : 13:00) - globenewswire.com
VIRX | $0.8363 -1.36% -1.33% 55K
|
Manufacturing
|
| O: 0.0%
H: 3.37%
C: -8.43%
t-cell trial therapeutics
Coya Therapeutics Licenses Intellectual Property Rights for Use of Next Generation Immune Modulatory Biologics in Combination with COYA 301 to Enhance Regulatory T Cells (Tregs) in Inflammatory Diseases
Published: 2024-02-13 (Crawled : 14:00) - biospace.com/
COYA | News | $8.41 4.86% 3.14% 120K
|
|
| O: 8.8%
H: 0.0%
C: -5.66%
therapeutics
Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors
Published: 2024-01-25 (Crawled : 14:00) - globenewswire.com
ELTX | $9.25 0.33% 0.32% 25K
|
|
| O: 1.52%
H: 19.1%
C: 14.93%
tumors publication cell preclinical therapeutics therapy
GenFleet Therapeutics Announces GFH009 Granted with FDA Fast Track, Orphan Drug Designations for Treating R/R Peripheral T-cell Lymphomas and Acute Myeloid Leukemia
Published: 2024-01-11 (Crawled : 11:00) - prnewswire.com
SLS | $1.54 -5.52% -5.84% 1.3M
|
Health Technology
|
| O: 1.84%
H: 1.25%
C: -4.34%
gfh009 fda drug t-cell granted lymphomas leukemia therapeutics
TG Therapeutics Announces Global License Agreement with Precision BioSciences for the Development and Commercialization of Precision’s Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of Autoimmune Diseases
Published: 2024-01-09 (Crawled : 12:00) - globenewswire.com
TGTX | $13.98 -1.9% -1.86% 2.4M
|
Health Technology
|
| O: -8.22%
H: 9.05%
C: 7.47%
DTIL | $9.82 -4.01% -4.28% 31K
|
Health Technology
|
| O: 10.0%
H: 14.23%
C: 0.09%
cd19 license cell treatment global commercialization program therapeutics agreement therapy
Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, the Industry's First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma
Published: 2024-01-04 (Crawled : 21:00) - globenewswire.com
ALLO | $3.04 -9.79% -10.86% 2.1M
|
Health Technology
|
| O: -17.4%
H: 4.64%
C: 4.11%
first trial therapeutics platform
Oncternal Therapeutics Updates the Status of its Phase 1/2 Study of ONCT-808, a ROR1-Targeting Autologous CAR T, in Patients with Relapsed or Refractory Aggressive B-cell Lymphoma
Published: 2023-12-26 (Crawled : 14:00) - globenewswire.com
ONCT | $8.545 -2.51% -0.11% 1.6K
|
Health Technology
|
| O: -16.39%
H: 19.98%
C: 18.2%
onct-808 therapeutics study
CytoMed Therapeutics Signs HOA and MOU to Advance Research on Allogeneic Gamma Delta T Cell Technology
Published: 2023-12-05 (Crawled : 12:30) - prnewswire.com
GDTC | $2.15 -2.04% 990
|
|
| O: 0.82%
H: 0.82%
C: -3.27%
cell research technology therapeutics
Coeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023
Published: 2023-10-31 (Crawled : 13:00) - prnewswire.com
COEP | $0.327 -2.39% -2.42% 150K
|
|
| O: -1.12%
H: 0.0%
C: -8.71%
cd20 her2 tumor research therapeutics potential growth
Harpoon Therapeutics Announces Updated Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023
Published: 2023-10-21 (Crawled : 16:20) - globenewswire.com
HARP | $23.01 0.07% 6.6M
|
Health Technology
| Email alert
Add to watchlist
hpn328 congress cell trial therapeutics response
EvolveImmune Therapeutics to Present New Preclinical and Translational Data Highlighting Precision Medicine Potential of its Novel Costimulatory T Cell Engager Platform at 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Published: 2023-10-18 (Crawled : 15:00) - biospace.com/
IMUN | $0.093 214.52% 1.8K
|
Manufacturing
| Email alert
Add to watchlist
cancer cell preclinical immunotherapy meeting therapeutics potential platform
Harpoon Therapeutics to Present Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023
Published: 2023-10-09 (Crawled : 20:00) - globenewswire.com
HARP | $23.01 0.07% 6.6M
|
Health Technology
|
| O: -2.12%
H: 11.81%
C: 1.86%
hpn328 congress cell trial therapeutics response
Nektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy
Published: 2023-10-02 (Crawled : 14:00) - biospace.com/
LLY | News | $732.2 -1.81% -0.84% 1.7M
|
Health Technology
|
| O: -1.77%
H: 0.0%
C: 0.0%
NKTR | News | $1.38 -2.82% -2.16% 960K
|
Health Technology
|
| O: -2.01%
H: 4.52%
C: -2.35%
t-cell congress therapeutics therapy
Gainers vs Losers
| 61% | 39% |
Top 10 Gainers
CSSE 4 | $0.4253 179.25% 64.77% 210M
|
Consumer Services
BOF | $2.08 77.78% 41.21% 110M
|
ILAG | $0.54 12.27% 40.62% 3.7M
|
LICN | $0.999 78.39% 40.49% 15M
|
AMST | $3.4 70.0% 39.58% 70M
|
Technology Services
MTC | $3.6 60.71% 38.04% 9.1M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.458 14.5% 30.92% 91K
|
Health Services
WHLM | $6.25 35.87% 28.46% 700K
|
Commercial Services
MULN | News | $3.77 38.1% 27.78% 13M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.